Advertisement

Topics

Roche says FDA grants priority review to hemophilia drug emicizumab

02:18 EDT 24 Aug 2017 | Reuters

ZURICH (Reuters) - Swiss pharma group Roche said the U.S. Food and Drug Administration (FDA) granted priority review to its emicizumab for hemophilia A with inhibitors.

Original Article: Roche says FDA grants priority review to hemophilia drug emicizumab

NEXT ARTICLE

More From BioPortfolio on "Roche says FDA grants priority review to hemophilia drug emicizumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...